Kochevar I E, Morison W L, Lamm J L, McAuliffe D J, Western A, Hood A F
Arch Dermatol. 1986 Nov;122(11):1283-7.
The therapeutic use of piroxicam as a nonsteroidal anti-inflammatory agent is associated with the development of photosensitivity in less than 1% of patients. The eruption usually occurs within a few days of commencing treatment with the medication. This time course suggests a phototoxic reaction. Attempts to demonstrate the phototoxic effects of piroxicam in humans, laboratory animals, and in in vitro cell assays were unsuccessful. At high concentration, however, one metabolite of piroxicam was phototoxic in animal studies and in in vitro assays. A second metabolite was mildly phototoxic in laboratory animals. These results suggest a mechanism whereby piroxicam photosensitivity may be due to a metabolite preferentially formed or accumulated in affected patients.
吡罗昔康作为一种非甾体抗炎药用于治疗时，不到1%的患者会出现光敏反应。皮疹通常在开始使用该药物治疗后的几天内出现。这种时间进程提示为光毒性反应。在人体、实验动物及体外细胞试验中，试图证明吡罗昔康的光毒性作用均未成功。然而，在动物研究和体外试验中，吡罗昔康的一种高浓度代谢产物具有光毒性。另一种代谢产物在实验动物中具有轻度光毒性。这些结果提示了一种机制，即吡罗昔康引起的光敏反应可能是由于在受影响患者体内优先形成或积累的一种代谢产物所致。
